Deans' stroke musings: Researchers Show TB4 Provides Both Neuroprotection and Neurorestoration after Traumatic Brain Injury

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, February 15, 2012

Researchers Show TB4 Provides Both Neuroprotection and Neurorestoration after Traumatic Brain Injury

Whats good for TBI should be good enough to test for stroke.
http://www.businesswire.com/news/home/20120215005441/en/Researchers-Show-TB4-Neuroprotection-Neurorestoration-Traumatic-Brain
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) today announced that researchers have shown that Thymosin beta 4 (Tβ4) “provides both neuroprotection and neurorestoration after traumatic brain injury (TBI), indicating that Tβ4 has promising therapeutic potential in patients with TBI.”

“provides both neuroprotection and neurorestoration after traumatic brain injury (TBI), indicating that Tβ4 has promising therapeutic potential in patients with TBI.”

The aims of the study were to test if Tβ4 treatment initiated 6 hours after traumatic brain injury in rats reduces brain damage and improves functional recovery. The rats were divided into two treatment groups and one placebo group. Tβ4 or placebo was systemically administered 6, 24, and 48 hours after injury. Compared with the placebo group, Tβ4 treatment initiated 6 hours post-injury statistically significant improvement of sensorimotor functional recovery and spatial learning, reduced cortical lesion volume and hippocampal cell loss, and enhanced cell proliferation and neurogenesis in the injured brain tissue. The high dose of Tβ4 showed better beneficial effects compared with the low dose treatment.

The research was conducted by Xiong Y, Zhang Y, Mahmood A, Meng Y, Zhang ZG, Morris DC, Chopp MJ in the Department of Neurosurgery at the Henry Ford Hospital System (HFHS) in Detroit, Michigan pursuant to a material transfer agreement between the hospital and RegeneRx Biopharmaceuticals, Inc. and published in Neurosurg., 2012 Feb 10. [Epub ahead of print].

"This preclinical study on the use of Thymosin beta 4 for the treatment of traumatic brain injury adds to the growing body of literature demonstrating the use of Tβ4 in neurological injury. The collective evidence of the neurorestorative properties of Tβ4 in animal models of multiple sclerosis, stroke and traumatic brain injury are compelling and we look forward to evaluating this drug in clinical trials," stated Dr. Dan Morris, Senior Staff Physician, Department of Emergency Medicine at HFHS and one of the investigators in study.

About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development and has an extensive worldwide patent portfolio covering its products.

RGN-259 is a sterile, preservative-free topical eye drop for ophthalmic indications. Based on a recently completed Phase 2 clinical trial in patients with dry eye syndrome, RGN-259 was found to show statistically significant improvements in several signs and symptoms of dry eye, as well as positive trends in other outcome measures. We believe the positive results of this Phase 2 exploratory trial reflect RGN-259’s reported mechanisms of action and provide RegeneRx with FDA-approvable endpoints to be targeted in future clinical trials.

RGN-352 is an injectable formulation to treat cardiovascular and central nervous system diseases, as well as other medical indications. RegeneRx is initially targeting RGN-352 for the treatment of patients who have suffered an acute myocardial infarction, or heart attack. Recent pre-clinical efficacy data suggests that RGN-352 may also benefit patients with multiple sclerosis, stroke and traumatic brain injury. RegeneRx has successfully completed a Phase 1 clinical trial with RGN-352 in which the drug candidate was found to be safe and well-tolerated. In 2010, RegeneRx received a $3 million, three-year development grant from the NIH to support the company's acute myocardial infarction program.